The Glaucoma Research Foundation announces $1.3 million in research grants for 2022
March 9, 2022 /PRNewswire/ — Glaucoma Research Foundation (GRF) today announced a total of $1.3 million in annual research grants to support 10 researchers at leading universities across the United States.
GRF is awarding $1 million to the four Catalyst for a Cure Principal Investigators ($250,000 to each lab) to continue their research to restore vision in glaucoma. One-year Shaffer Grants from the GRF in the amount of $50,000 each will be awarded to six individual grant recipients to support their research into potential new glaucoma treatment targets.
“Glaucoma Research Foundation is funding six investigators at prestigious medical research centers with our one-year Shaffer Grants,” said Andrew G. Iwach, MD, Chairman of the GRF Board of Directors. “In addition, we will continue to fund the four principal investigators engaged in our multi-year Catalyst for a Cure Vision Restoration initiative. With this diverse research portfolio, we are doing our best to invest in research that brings us closer to our goal of finding a cure for glaucoma and restoring vision, while developing better solutions for glaucoma patients today. .”
Catalyst for a healing research collaboration
“The Catalyst for a Cure team continues to make excellent progress in their collaborative research,” said Thomas M. Brunner, President and CEO of GRF. “Their efforts are our best hope for a cure for glaucoma.” he said. The four Principal Investigators of Catalyst for a Cure are Xin Duan, PhDUniversity of California, San Francisco; Yang Hu, MD, Ph.D.Stanford University School of Medicine; Anna La Torre, PhD, University of California, Davis; and Derek Welsbie, MD, PhDShiley Eye Institute at UC San Diego.
The 2022 Shaffer Grants for Innovative Glaucoma Research
Here is a summary of the Shaffer Research Grant projects that the Glaucoma Research Foundation is funding at $50,000 each:
Kun-Che Chang, PhD
University of Pittsburgh
A novel therapeutic gene for RGC survival and axon regeneration in glaucoma
Mr. Elizabeth Fini, PhD
Mechanisms of steroid-induced ocular hypertension
Sidney Kuo, PhD
University of Minnesota
Early structural changes of Müllerian glial cells in glaucoma
Myoungsup Sim, PhD
Cilia-mediated primary nitric oxide production in Schlemm’s canal cells
Brian Soetikno, MD, Ph.D.
Visible light OCT for glaucoma
Qing Wang, MD, Ph.D.
New tools to identify and target astrocyte subtypes to treat glaucoma
SOURCE Glaucoma Research Foundation